GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cognetivity Neurosciences Ltd (XCNQ:CGN) » Definitions » Net Current Asset Value

Cognetivity Neurosciences (XCNQ:CGN) Net Current Asset Value : C$-0.17 (As of Oct. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Cognetivity Neurosciences Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Cognetivity Neurosciences's net current asset value per share for the quarter that ended in Oct. 2023 was C$-0.17.

The historical rank and industry rank for Cognetivity Neurosciences's Net Current Asset Value or its related term are showing as below:

During the past 7 years, the highest Price-to-Net-Current-Asset-Value Ratio of Cognetivity Neurosciences was 61.00. The lowest was 5.00. And the median was 21.75.

XCNQ:CGN's Price-to-Net-Current-Asset-Value is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 6.395
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Cognetivity Neurosciences Net Current Asset Value Historical Data

The historical data trend for Cognetivity Neurosciences's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cognetivity Neurosciences Net Current Asset Value Chart

Cognetivity Neurosciences Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
Net Current Asset Value
Get a 7-Day Free Trial 0.01 -0.01 0.01 -0.07 -0.12

Cognetivity Neurosciences Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 -0.12 -0.13 -0.15 -0.17

Competitive Comparison of Cognetivity Neurosciences's Net Current Asset Value

For the Health Information Services subindustry, Cognetivity Neurosciences's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cognetivity Neurosciences's Price-to-Net-Current-Asset-Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cognetivity Neurosciences's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Cognetivity Neurosciences's Price-to-Net-Current-Asset-Value falls into.



Cognetivity Neurosciences Net Current Asset Value Calculation

Cognetivity Neurosciences's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Jan. 2023 is calculated as

Net Current Asset Value Per Share(A: Jan. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(2.657-12.719-0-0)/85.0492
=-0.12

Cognetivity Neurosciences's Net Current Asset Value (NCAV) per share for the quarter that ended in Oct. 2023 is calculated as

Net Current Asset Value Per Share(Q: Oct. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(0.303-15.682-0-0)/89.5566
=-0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cognetivity Neurosciences  (XCNQ:CGN) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Cognetivity Neurosciences Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Cognetivity Neurosciences's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Cognetivity Neurosciences (XCNQ:CGN) Business Description

Traded in Other Exchanges
Address
800 West Pender Street, Suite 1430, Vancouver, BC, CAN, V6C 2V6
Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.

Cognetivity Neurosciences (XCNQ:CGN) Headlines

No Headlines